Introduction
============

Pathological myopia is one of the leading causes of visual impairment worldwide, and choroidal neovascularisation (CNV) is one of the most sight-threatening complications in patients affected with pathological myopia.^[@bib1]^ The estimated risk for development of CNV from pathological myopia has been estimated as 4--10%, and the natural course of subfoveal CNV is generally poor.^[@bib2]^ Indeed, a large proportion of patients with myopia will have progression of myopic maculopathy, and a consequent visual loss.

Photodynamic therapy (PDT) has been one of the treatments of choice for myopic CNV over the past decade, and several studies have demonstrated that compared with placebo, PDT can reduce the risk of visual loss.^[@bib3],\ [@bib4]^ However, patients treated with PDT do not gain better mean visual acuity, and PDT does not prevent visual loss for longer than 2 years.^[@bib5]^

In recent years, the short-term efficacy of intravitreal anti-vascular endothelial growth factor (VEGF) agents has been shown for the arrest of myopic CNV, which have included bevacizumab^[@bib6]^ and ranibizumab.^[@bib7]^ The majority of the studies with these agents have reported significant mean visual acuity improvements at 12 months. Other more recent studies have shown longer-term visual results for treatment of myopic CNV for up to 2 years after intravitreal injections of bevacizumab.^[@bib8],\ [@bib9]^ However, some discrepancies have been detected for such longer-term visual outcomes; indeed, it has been demonstrated that the initial visual gain with bevacizumab is not significantly maintained at 2 years.^[@bib9],\ [@bib10]^ This appears to be because patients with myopic CNV who were treated with this anti-VEGF agent had undergone prior treatments, with some of these treatments being for non-subfoveal CNV.

The use of aflibercept (Eylea; Regeneron, Tarrytown, NY, USA; Bayer, Basel, Switzerland) has been introduced more recently, which is a recombinant fusion protein that binds all isoforms of VEGF, and also placental growth factor.^[@bib11]^ Aflibercept recently obtained US Food and Drug Administration approval for the treatment of neovascular age-related macular degeneration (AMD).^[@bib12]^ With treatment of aflibercept every 2 months following 3-monthly loading doses, it was shown to be non-inferior to monthly injections of ranibizumab, in terms of patients who maintained or improved their vision at 12 months. These aflibercept benefits were also maintained to 2 years.^[@bib12]^

However, there remain discrepancies in the literature about the efficacy of ranibizumab and bevacizumab for maintenance of good visual acuity over 2 years of treatment of patients with myopic CNV. Thus, considering also the relative lack of data for aflibercept treatment for these patients, we investigated the long-term visual outcome of patients with myopic CNV treated with aflibercept.

Materials and methods
=====================

This was a retrospective study of consecutive patients with subfoveal/juxtafoveal CNV secondary to pathological myopia who received intravitreal aflibercept injections. The treatments were carried out in the Department of Ophthalmology, Polytechnic University of Marche, Ancona (Italy), and informed consent was obtained from all of the patients before treatment.

The inclusion criteria included: treatment-naive patients with follow-up of ≥18 months; myopia with a spherical equivalent refractive error of ≥--5 D; active CNV, as documented by fluorescein angiography and SD-OCT (spectral-domain optical coherence tomography); subfoveal--juxtafoveal CNV; and best-corrected visual acuity (BCVA) 20/800 or better. The exclusion criteria included: prior treatments for CNV, including PDT and thermal laser photocoagulation; history of intraocular surgery; extrafoveal CNV; CNV from ocular pathology other than pathological myopia, such as AMD, choroiditis, angioid streaks, and trauma; and hereditary disease in the studied and fellow eye.

At baseline and at all subsequent visits, complete ophthalmic examinations were carried out, which included Snellen BCVA (converted to the logarithm of the minimum angle of resolution; logMAR), slit-lamp biomicroscopy, tonometry, fundus examination, and fluorescein angiography. Fundus photography and SD-OCT (Topcon America, Paramus, NJ, USA; Heidelberg Engineering Inc., Dossenheim, Germany) were performed at baseline, and at 1 week and 1, 2, 3, 6, 12, and 18 months after aflibercept injection.

Intravitreal injections of aflibercept 2 mg were carried out using a 30-gauge needle, at 4 mm from the limbus and under aseptic conditions. Retreatment with aflibercept was performed based on the presence of active leakage on fluorescein angiography, persistent subretinal fluid on SD-OCT, or new haemorrhage, with minimum 3-monthly retreatments maintained.

Statistical analysis was carried out using SPSS (Version 17.0; SPSS Inc., Chicago, IL, USA). The patients were analysed according to both the total patient group and the age groups of \<50 years *vs* ≥50 years. Paired *t*-tests were performed to evaluate the effects of the post-treatment visual outcome *vs* baseline (pre-treatment). The differences in the visual outcomes between the two age groups were compared using two-sample *t*-tests. Linear regression was performed to determine the effects on visual outcome of baseline BCVA, age, spherical equivalent, and number of injections. A P-value of \<0.05 was considered as statistically significant.

We certify that all applicable institutional and governmental regulations concerning the ethical use of human volunteers were followed during this study.

Results
=======

In all, 38 eyes from 38 patients (24 women and 14 men) were included in the study, and the baseline and clinical characteristics of these patients are given in [Table 1](#tbl1){ref-type="table"}. For the total patient group, the baseline mean age (±standard deviation \[SD\]) was 45.8 years (±20.5 years; range, 22--79 years). The CNV was seen for 30 right eyes (79%) and 8 left eyes (21%). The baseline mean spherical equivalent refractive index was −7.79 D (±3.75 SD; range, −5.00 to −12.50). The mean follow-up time was 21±1.9 months.

For the total patient group, the mean BCVA (±SD) improved significantly, from 0.69±0.30 logMAR at baseline to 0.15±0.09 logMAR at 18 months (*P*\<0.001) ([Figure 1](#fig1){ref-type="fig"}). The mean central foveal thickness decreased significantly from 276 *μ*m at baseline to 215 *μ*m at 18 months (*P*\<0.001) ([Table 2](#tbl2){ref-type="table"}). Paired *t*-tests also demonstrated significant improvement in BCVA compared with baseline at 1, 3, 6, 12, and 18 months (*P*\<0.001). The greatest improvements were seen within the first 3 months of the initial aflibercept injection, and the BCVA remained stable thereafter. Overall, 55% (21/38) of the patients achieved resolution of their myopic CNV with a single aflibercept injection. Thus, 19 of the 38 patients (50%) received \>1 aflibercept injection, with a total of 79 aflibercept injections given to the 18 months of follow-up (ie, mean, 2.1 aflibercept injections/patient). In detail, over the 18 months of follow-up, 50% of patients received one injection, 18.4% received two injections, 10.5% received three injections, 15.8% received four injections, and 5.3% received five injections.

The further analysis provided 20 eyes for patients aged \<50 years, and 18 eyes for those aged ≥50 years. The mean number of aflibercept injections was 1.5 for the \<50 years myopic CNV group, and 2.7 for the ≥50 years myopic CNV group (*P* \<0.001). Indeed, 60% (12/20) of the treated eyes of the patients \<50 years old obtained resolution with just one injection, which was significantly greater than that seen for the treated eyes of the patients ≥50 years old (60 *vs* 49%, respectively; *P*\<0.05).

The mean BCVA improvement was greater in the younger group (\<50 years) compared with the ≥50 years (0.64 *vs* 0.38, respectively; *P*\<0.05) ([Figure 2](#fig2){ref-type="fig"}). In the 18 months of follow-up, the \<50 year patients showed significantly better BCVA improvement than those of ≥50 years (0.21±0.12 *vs* 0.35±0.12, respectively; *P*\<0.05).

In the comparison of spherical equivalent refraction between the patients of \<50 *vs* ≥50 years, at baseline the young patients were more myopic than the old patients (−9.9 *vs* −5.5), although this difference did not reach statistical significance. With stratification by age, the correlation between the spherical equivalent refraction and the final visual acuity showed significance only for the patients of \<50 years (*P*\<0.001; Levene\'s correlation) ([Figure 3](#fig3){ref-type="fig"}), as the correlation lost significance for the patients of ≥50 years. This suggests that spherical equivalent refraction is also predictive of the final visual acuity, and that higher myopia relates to worse visual acuity in young patients.

In the linear regression analysis of the total patient group, after adjusting for age, spherical equivalent refraction, and number of injections, baseline BCVA was the most predictive factor for the visual outcome (*P*\<0.001). Baseline spherical equivalent refraction did not correlate with initial and final BCVA (*P*\>0.05; Levene\'s correlation). No relevant ocular or systemic complications were detected.

Discussion
==========

Several treatments have been proposed for myopic CNV, such as laser photocoagulation, surgical removal of CNV, macular translocation, and PDT without and with intravitreal triamcinolone acetonide. However, the most appropriate treatment remains to be established. Laser photocoagulation should not be considered in juxtafoveal cases, as the long-term expansion of the laser scar can cause decreased visual acuity; this is however not a concern for extrafoveal cases.^[@bib13]^

PDT with benzoporphyrin, a derivative verteporfin, is a treatment option for subfoveal CNV in pathological myopia. Treatment with PDT has been described to provide more stable visual acuity compared with placebo.^[@bib4]^ However, more recently, intravitreal injections of anti-VEGF agents have been proposed as the main therapy for the treatment of myopic CNV.^[@bib14],\ [@bib15]^ Indeed, previous reports have shown that these agents can provide good outcomes in the treatment of myopic CNV. However, most of these studies included patients who had been previously treated with PDT, and also included older subjects.^[@bib16],\ [@bib17],\ [@bib18]^

Previous studies by Gharbiya *et al*^[@bib8]^ and Nakanishi *et al*^[@bib16]^ showed that patients with myopic CNV can gain significant visual improvement to 2 years following monthly intravitreal injections of bevacizumab. However, Ruiz-Moreno *et al*^[@bib9]^ and Ikuno *et al*^[@bib10]^ demonstrated that the initial visual improvements in these patients were no longer significant after 2 years of monthly intravitreal bevacizumab therapy. This lack of significant visual improvement in these two latter studies might be explained by the relatively small sample sizes for the patients studied by Ruiz-Moreno *et al*^[@bib9]^ and the inclusion of only patients \>50 years old by Ikuno *et al.*^[@bib10]^ In the present study, we detected better visual acuity in patients aged \<50 years in the first 18 months of follow-up, which is in agreement with the clinical findings of Yoshida *et al*,^[@bib19]^ who also showed similar clinical progress based on the patient\'s age.

This can be explained by several factors, such as decreased integrity and function of the myopic retinal pigment epithelium in older patients, which might reduce the inhibition of angiogenesis, with the consequent larger and more active CNV, as well as a delay in the regression of CNV in these older patients.^[@bib20]^ Indeed, myopic CNV in older patients can present clinical and pathophysiological features of both AMD and high myopia, with poor natural outcome. Older patients tend to develop chorioretinal atrophy degeneration, which is a condition that negatively influences the final visual acuity in these patients. In the present study, the patients were balanced for age and sex, and these factors did not influence the significantly better final visual acuity at 18 months, compared with baseline.

Our findings show that the patients with myopic subfoveal--juxtafoveal CNV had a mean improvement of five lines at 18 months from baseline, following the intravitreal aflibercept injections. Of note, the treatment of subfoveal myopic CNV with PDT has also been reported to show no significant improvements at 2 years,^[@bib5]^ with several studies demonstrating such inferior visual outcomes correlated to PDT.^[@bib21],\ [@bib22]^ An explanation here might relate to the enlargement of chorioretinal atrophy around the CNV following PDT, as eyes affected by pathological myopia do not show any increased scarring after treatment: the reduced number of injections might explain the absence of chorioretinal atrophy associated with CNV. On the basis of a prospective randomised clinical trial, the RADIANCE study, that demonstrated a superiority of intravitreal ranibizumab over PDT, ranibizumab has recently received approval in the European Union as the first effective anti-VEGF treatment for myopic CNV. The study proved that 40% of patients treated with ranibizumab, as opposed to 15% of PDT, gained 15 or more letters of visual acuity at 3 months.^[@bib23]^ The mean visual acuity gain was \~14 Early Treatment Diabetic Retinopathy Study letters at 1 year at a mean of 3.5 ranibizumab injections. In detail, 50% of the patients required 1--2 injections, 36% required 3--5 injections, and 14% required 6--12 injections over the 12-month study. In our series of patients, 68.4% of them received 1--2 injections of aflibercept, 31.6% required 3--5 injections, and 0% required 6--12 injections over the 18-month follow-up. Indeed, CNV myopic eyes treated with aflibercept required a significant lower number of injections considering the longer follow-up of 18 months.

A potential risk associated with the treatment of myopic CNV with anti-VEGFs is the formation of marginal crack lines after treatment-related contraction of the myopic CNV, which is considered as early damage of the retinal pigment epithelium that might lead to expanding macular chorioretinal atrophy. This factor, in conjunction with treatment-related cumulative damage to the photoreceptors and the underlying retinal pigment epithelium, might compromise the long-term results, as underlined by the relatively few aflibercept injections needed in the present study. Several studies^[@bib24],\ [@bib25],\ [@bib26],\ [@bib27]^ and an open-label, non-comparative phase II trial known as REPAIR (Ranibizumab for the trEatmentof CNV secondary to pathological myopia; an Individualised Regimen)^[@bib28],\ [@bib29]^ have shown beneficial results of intravitreal ranibizumab for myopic CNV. Twelve-month data from the phase II study indicated that ranibizumab was associated with significant improvements of BCVA score and central macular thickness. Furthermore, fewer eyes had subretinal fluid, intraretinal cysts, or oedema at 12 months than at baseline (7.7 *vs* 67.7%, 13.8 *vs* 52.3%, 7.7 *vs* 87.7%, respectively). Nevertheless, further long-term data for ranibizumab are missing, including data relating to any potential for geographic atrophy, the risk of which was increased with ranibizumab in a recent AMD study.^[@bib30]^ To date, there are no data about the long-term effect of ranibizumab on myopic CNV. A prospective, observational study (LUMINOUS) is ongoing for the evaluation of long-term safety and efficacy of ranibizumab in routine clinical practice.^[@bib31]^

For the reduced number of aflibercept injections that were required, this can be explained by the decreased aggressiveness of myopic CNV compared with AMD and by the characteristics of aflibercept compared with the other anti-VEGF agents. Indeed, aflibercept binds placental growth factor in addition to both the VEGF-A and VEGF-B isoforms. Placental growth factor is present in human CNV, and animal studies have demonstrated that it can promote the development of experimental CNV. Furthermore, aflibercept has a high affinity for VEGF (Kd, 0.5 pM), which is considerably greater than that of ranibizumab and bevacizumab for VEGF, and also of VEGF for its receptors.^[@bib23]^ This provides effective blocking of VEGF with longer duration of action, which thus also promotes extended dosing intervals. Indeed, the 1-year results from the VIEW 1 and VIEW 2 studies showed that in the treatment of CNV due to AMD, aflibercept was non-inferior under similar dosing regimens to ranibizumab.^[@bib24],\ [@bib25],\ [@bib26],\ [@bib27],\ [@bib28]^ Here, aflibercept maintained the visual gains obtained in the first year of the study with significantly fewer injections compared with ranibizumab.

The 1-year data from the CLEAR-IT 2 study also demonstrated good visual and anatomical outcome with aflibercept. After one injection per month for 3 months, only one or two more injections were needed per eye (with the treatment on an as-required basis, as in the present study), with a mean time for reinjection of 129 days (ie, every \~4.5 months).^[@bib32]^ These outcomes were similar to the ANCHOR,^[@bib33]^ MARINA,^[@bib34]^ and PRONTO^[@bib35]^ ranibizumab trials for the initial monthly regime of three injections, and in particular, these all indicated the need for less frequent dosing of aflibercept.

This has been confirmed also in the present study for the treatment of myopic CNV. In particular, we have shown the need for significantly fewer aflibercept injections for the \<50 years myopic CNV group compared with the ≥50 years myopic CNV, and over half of the total treated eyes obtained resolution with just one aflibercept injection. This suggests that a three-injection loading phase is not necessary for young patients affected by myopic CNV who are treated with aflibercept. The good function of retinal pigment epithelium cells in young patients will also allow greater inhibition of CNV growth compared with the older subjects.

Aflibercept is a promising option for patients with naive myopic CNV due to its high binding affinity and extended duration of action. This latter quality is particularly relevant, because pathological myopia is a chronic disease and it mainly affects patients of working age. Thus for these patients, aflibercept can be considered as a valid alternative to other anti-VEGF agents, also with apparently fewer injections needed for the treatment. Indeed, as in previous trials in patients with AMD,^[@bib36],\ [@bib37]^ and although not examined directly here for these patients with naive myopic CNV, the collected data indicate similar visual acuity obtained for aflibercept when compared with ranibizumab and bevacizumab, but with a longer duration of action for aflibercept, and thus fewer injections needed. Furthermore, considering the reduced number of aflibercept injections on a *pro re nata* basis observed in our study, this will also reduce the burden on the health services and reduce the discomfort for the patient.

Therefore, this combination of the efficacy, duration of action, economics, patient benefit, and safety profiles of intravitreal aflibercept now indicate the need for a shift in the treatment choice for patients with naive myopic CNV.
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![Initial and final BCVA for the total patient group.](eye2015199f1){#fig1}

![Comparison of the mean BCVA improvement in the young group (\<50 years) compared with the ≥50-year-old group.](eye2015199f2){#fig2}

![Correlation between the spherical equivalent refraction and the final visual acuity for the patients of \<50 years.](eye2015199f3){#fig3}

###### Baseline demographic and clinical data for the full patient group, and for the \<50 and ≥50 years patient groups

  *Parameter*                             *Total patient group (38 eyes)*  *Patients \<50 years (20 eyes)*   *Patients ≥50 years (18 eyes)*   P*-value (\<50 vs ≥50)*
  -------------------------------------- --------------------------------- --------------------------------- -------------------------------- -------------------------
  Age (years)                                          45.76               27.25 (±6.28)                     66.33 (±4.63)                    \<0.05
  Gender (male: *n* \[%\])                          14 \[36.8\]            6 \[30.0\]                        8 \[44.44\]                      NS
  Eye side (right: *n* \[%\])                       30 \[79.0\]            20 \[100\]                        10 \[55.55\]                     NS
  Spherical equivalent (D)                         −7.79 (±3.75)           --9.93 (±0.85)                    −5.58 (±2.19)                     
  BCVA (logMAR)                                    0.69 (±0.30)            0.86 (±0.22)                      0.73 (±0.25)                     NS
  Mean central foveal thickness (*μ*m)                  276                285                               267                               

Abbreviation: NS, non-significant. Data are means (±SD) or as indicated.

###### Clinical data after 18 months of follow-up for the full patient group, and for the \<50 and ≥50 years patient groups

  *Parameter*                             *Total patient group*  *Patients \<50* *years (20 eyes)*   *Patients ≥50* *years (18 eyes)*   P-*value* *(\<50 years vs ≥50 years)*   
  -------------------------------------- ----------------------- ----------------------------------- ---------------------------------- --------------------------------------- ---------
  BCVA (logMAR)                                 0.15±0.09        \<0.001                             0.21 (±0.12)                       0.34 (±0.12)                            \<0.001
  Mean central foveal thickness (*μ*m)             215           \<0.001                             210 (±13.00)                       211 (±12.78)                            \>0.05

Data are means (±SD) or as indicated.
